Actinic Keratosis Treatment Market 2018 | Promises a Striking Fortune USD 9 Billion | Forecasts by 2022

“Market Research Future (MRFR)”
The intense need for in-depth understanding of the “Actinic Keratosis Treatment Market -Forecast to 2022″ coupled with its high growth potential necessitated the development of this report by Market Research Future. The report specifically focuses on the key industry development trends and forces that shapes the market, but not limited to only commercial nature, but which encompasses a broad range such as social, technological and others. adds “Anti-Asthma Drugs Market -2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022” reports to its database.

Regional Analysis of Global Actinic Keratosis Treatment Market:

Globally, Americas is the largest market for actinic keratosis treatment. The Americas market for actinic keratosis treatment market is expected to reach around USD 3.8 billion by the end of the forecast period of 2016-2022. Europe is the second-largest market for actinic keratosis treatment. Asia pacific region is expected to be fastest growing region in actinic keratosis treatment market.

The report for Global Actinic Keratosis Treatment Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insights of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Key Players in the Actinic Keratosis Market:

LEO Pharma Inc., Clinuvel Pharmaceuticals Ltd, Biofrontera AG, DUSA Pharmaceuticals, Inc., TOLMAR Pharmaceuticals, Inc., Valeant, Galderma S.A., Perrigo Company plc. are key player in the market. Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Developments of key players:


Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands. The company focus on the production of  innovative solutions in the field of dermatology for the treatment of various skin diseases such as acne, rosacea, psoriasis, steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care.

January 2017: Galderma launched two new dermal fillers. In December, Galderma received FDA approval for a pair of next-generation hyaluronic acid (HA) dermal fillers: Restylane Refyne and Restylane Defyne.

January 2017: Galderma announces approval of Azzalure in Europe for treatment of lateral canthal lines in adults. Azzalure, a product in-licensed from Ipsen, received positive opinion from the French regulatory authority, ANSM, for treatment of lateral canthal lines (crow’s feet), either alone or in combination with treatment of Glabellar lines.

July 2016: Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases. The primary aim of this agreement is to improve atopic dermatitis by breaking the itch-scratch cycle which has great expectation for Nemolizumab.

January 2016: Maruho and Galderma to Join Forces in a Strategic Alliance in Japan. One of the major reasons of this strategic alliance is that Galderma will permit Maruho to additionally promote their products in japan in the field of dermatology of medicines for infectious disease, which include systemic fungal infections.

Actinic Keratosis Treatment Market in Asia Pacific Expected to Exhibit Fastest Growth:

Asia Pacific is the fastest growing market for actinic keratosis treatment market due to large patients’ population and growing geriatric population. China and India drive the major market and contribute largest share in the Asia Pacific actinic keratosis treatment market. Rapidly developing technology and increasing treatment methods are driving the growth of the market.

According to survey carried out by Pfizer, in 2012, 6.7 million of cancer cases was registered in Asia Pacific region which will increasing continuously. Additionally, according to the American Cancer Society, in 2015, 4.2 newly diagnosed invasive cancer cases were registered in China.

According to World Health Organization (WHO), the prevalence of skin cancer is increasing at a rate of 6.52% in Asia Pacific. Beside this continuous increasing demand for better treatment and increasing government support for R&D has provided fuel for the growth of market.


Global Actinic Keratosis Treatment Market – Overview:

Cancer is becoming one of the major problems across the globe. In more than 90% cases skin cancer is caused due to exposure to ultraviolet radiation from the sun. There are three major type of skin cancer namely basal cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. Exposure to the radiation during childhood can cause melanomas and basal-cell cancers. People with light skin are at higher risk for skin cancer. The global market for actinic keratosis treatment market is expected to reach around

Also known as solar keratosis, actinic keratosis is a type of skin cancer in which the skin gets rough and develops scaly patches as a result of exposure to the sun. It’s most commonly found on face, lips, ears, back of hands, forearms, and scalp or neck.

The global skin cancer market is driven by increasing prevalence of skin cancer, rising healthcare expenditure in developing economies and increasing government support. While adverse effect associated with treatment, long approval time for the drugs and strict regulatory rules has restrained the growth of the market.

According to the World Health Organization (WHO), the prevalence of skin cancer is increasing at a rate of 6.52%. Beside this continuous increasing demand for better treatment and increasing government support for R&D has provided fuel for the growth of market.

According to the American Academy of Dermatology (AAD), skin diseases affects one in every fourth American. The prevalence of skin diseases is also found to be increasing in Canada. According to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime.


Global Actinic Keratosis treatment market has been segmented on the basis of surgical procedures which comprises photodynamic therapy, cryotherapy, curettage and desiccation, laser surgery, combination therapy and others. On the basis of prescription products; market is segmented into fluorouracil cream, imiquimod cream, ingenol mebutate gel, diclofenac gel and others. On the basis of end users; market is segmented into hospitals, clinics, oncology centers, dermatology service centers and others.


Chapter 1. Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

Chapter 2. Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

Chapter 3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

Chapter 4. Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of Suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

Chapter 5. Global Actinic Keratosis Treatment Market, By Surgical Procedure           

5.1 Introduction

5.1.1 Photodynamic Therapy

5.1.2 Cryotherapy

5.1.3 Curettage and Desiccation

5.1.4 Laser Surgery

5.1.5 Combination Therapy

5.1.6 Others



About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India